A two-drug combination frequently used in anti-aging research causes brain damage in mice, report University of Connecticut ...
Genentech Inc. is covering more bases in multiple sclerosis, with its latest swing on fenebrutinib hitting a rare phase III noninferiority win against Ocrevus (ocrelizumab) in primary progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results